Prime Medicine, Inc. (PRME)
(Delayed Data from NSDQ)
$4.43 USD
+0.13 (2.91%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.42 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Prime Medicine, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 5 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 5 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 205 | 117 | 84 | 6 | 0 |
Income After Depreciation & Amortization | -205 | -117 | -84 | -1 | 0 |
Non-Operating Income | 6 | -6 | -81 | -1 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -198 | -123 | -166 | -2 | NA |
Income Taxes | 0 | -1 | 0 | 2 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -198 | -122 | -165 | -3 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -198 | -122 | -165 | -3 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -204 | -115 | -83 | -1 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 2 | 1 | 0 | NA |
Income After Depreciation & Amortization | -205 | -117 | -84 | -1 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 90.97 | 33.89 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.03 | -4.19 | NA | NA | NA |
Diluted Net EPS (GAAP) | -2.18 | -4.19 | NA | NA | NA |
Fiscal Year end for Prime Medicine, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 54.54 | 51.46 | 45.26 | 40.03 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -54.54 | -51.46 | -45.26 | -40.03 |
Non-Operating Income | NA | 2.40 | 0.64 | 2.90 | 0.43 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -65.64 | -50.82 | -42.35 | -39.60 |
Income Taxes | NA | 0.00 | -0.11 | 0.03 | -0.20 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -65.64 | -50.71 | -42.39 | -39.40 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -65.64 | -50.71 | -42.39 | -39.40 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 91.99 | 91.85 | 90.47 | 89.07 |
Diluted EPS Before Non-Recurring Items | NA | -0.56 | -0.55 | -0.47 | -0.44 |
Diluted Net EPS (GAAP) | NA | -0.72 | -0.55 | -0.47 | -0.44 |